Significance of serum phosphohexose isomerase in gastrointestinal cancer at different stages.
The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney, and breast cancer.
(PHI) is reported to be a dimeric enzyme involved in glycolysis (Cooke and Buckley, 1987).
The components are (1) tumor markers: HCG-lntact Hormone by IRMA, HCG-Total Hormone (intact, nicked intact, free [beta], nicked, and free [beta], fragments) by chemiluminescence, HCG-Urine test by chemiluminescence, PHI enzyme (phosphohexose isomerase or glucose phosphate isomerase) by enzyme kinetics, and CEA (carcinoembryonic antigen) by chemiluminescence; and (2) peripherally related assays: GGTP, TSH, and DHEA-S.
PHI: Phosphohexose isomerase, EC 126.96.36.199, is also known as glucose phosphate isomerase or phosphoglucose isomerase, and was originally isolated from a human melanoma cell line.
Enzyme activity Ensyme C2-4 (normal) Ex139 (hls) units [g.zup.-1] protein Amylase 34.7 35.3 Starch phosphorylase 15.7 15.3 Hexokinase 0.95 1.01 Phosphoglucomutase 0.84 0.80 Phosphohexose isomerase
1.88 1.87 Phosphofruetokinase 0.84 0.83 Aldolase 6.9 6.5 Triosephosphate isomerase 125 126 Fructose-1,6-bisphosphatase 2.8 2.7 UDP glucose pyrophosphorylase 0.5 0.5 Sucrose-P phosphalase 18 17 Invertase 61.4 87.3 Significance Ensyme of t-test Amylase NS Starch phosphorylase NS Hexokinase NS Phosphoglucomutase NS Phosphohexose isomerase
NS Phosphofruetokinase NS Aldolase NS Triosephosphate isomerase NS Fructose-1,6-bisphosphatase NS UDP glucose pyrophosphorylase NS Sucrose-P phosphalase NS Invertase (**) (*), (**) means significantly different at P = 0.05 and P = 0.01, respectively.